May 26, 2024
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is driven by the rising prevalence of smoking

Chronic Obstructive Pulmonary Disease (COPD) refers to a group of progressive lung diseases characterized by airflow limitation. The two main conditions included in COPD are chronic bronchitis and emphysema. COPD symptoms include breathlessness, chronic cough, sputum production and wheezing. Smoking is the leading cause of COPD globally and it accelerates the damage to lungs caused by COPD. COPD treatment aims to control symptoms and reduce risks from lung function decline. Prescription medicines for COPD include bronchodilators, corticosteroids and antibiotics. Lung rehabilitation programs and surgery are also beneficial for some patients. The global COPD treatment market play a crucial role in helping patients manage their condition and improve quality of life.

The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the Chronic Obstructive Pulmonary Disease (COPD) treatment market size is the rise of combination inhalers. Combination inhalers contain two or more medicines in single inhaler device. This helps improve patient compliance as patients only need to use single inhaler instead of multiple inhalers. Popular combination inhalers approved for COPD contain long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS). Combination inhalers have demonstrated better efficacy in reducing COPD exacerbations and improving quality of life compared to single ingredient inhalers. Their uptake is expected to grow significantly in the coming years.

Porter’s Analysis
Threat of new entrants: The COPD treatment market requires high R&D investments and established distribution networks, lowering the threat of new entrants.
Bargaining power of buyers: The bargaining power of buyers is moderate as COPD treatment options are diversified with large players.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of substitutes and low switching costs.
Threat of new substitutes: Threat of new substitutes is high due to focus on advancing COPD treatment therapies through innovations.
Competitive rivalry: The market is competitive with companies competing on the basis of portfolio, pricing and geographic presence.

Key Takeaways
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment market is expected to witness high growth over the forecast period of 2024 to 2031. The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031.

Regional analysis related content comprises increased healthcare expenditure, prevalence of COPD and medical reimbursement drive the U.S to dominate North America. However, Canada is also projected to contribute significantly during the forecast period. European region has high burden of COPD and is spearheaded by Germany, France, U.K, Italy and Spain. High funding for research and development along with supportive regulatory environment propels the regional market. Asia Pacific region has led by China and India led by increasing aged population, growing healthcare expenditure, changing lifestyle leading to increased smoking. The region demonstrates highest growth potential for COPD treatment.

Key players operating in the COPD treatment market include First Sensor AG, Bosch Sensortec GmbH, Honeywell International Inc., Murata Manufacturing Co. Ltd., ROHM Co. Ltd., Amphenol Corporation, InvenSense Inc. (TDK Corporation), Sensata Technologies Inc., NXP Semiconductors NV (Freescale), Goertek Inc., TE Connectivity Ltd., STMicroelectronics NV, Infineon Technologies AG, Omron Corporation, and Alps Alpine Co. Ltd. The market is concentrated and these global players compete based on their product portfolio for both pharmaceutical and device segments of the COPD treatment market.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research

2. We have leveraged AI tools to mine information and compile it